American Society of Clinical Oncology

Faculty Contribution(s): 3

1. Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.
Read More

2. Disparities by race, socioeconomic status, and insurance type in the receipt of National Comprehensive Cancer Network (NCCN) guideline adherent care and survival for select cancers in California.
Read More

Genitourinary Cancers Symposium

3. Personalized Medicine for Prostate Cancer Study (PMPC): The Role of Race, Genomics and Patient Complexity in Treatment Outcomes.
Read More

Nothing but the absolute best in patient care & treatment.

Disclaimer : All content posted on this website is commentary or opinion. This website does not give or attempt to give medical advice and your personal information is not stored. THIS WEBSITE IS NOT DESIGNED TO – AND DOES NOT – PROVIDE MEDICAL ADVICE.